Selected pharmacokinetic issues in patients with chronic kidney disease

Blood Purification

Volumn 25, Issue 1, 2006, Pages 133-138

  Churchwell, Mariann D ^a,b   Mueller, Bruce A ^b  

^a UNIVERSITY OF TOLEDO   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Chronic kidney disease; Pharmacokinetics; Pharmacotherapy

Indexed keywords

CALCIUM ACETATE; CALCIUM CARBONATE; CIPROFLOXACIN; CODEINE; DEXTROPROPOXYPHENE; DIGOXIN; FERROUS SULFATE; FUROSEMIDE; MIDAZOLAM; MORPHINE; PETHIDINE; PHENYTOIN; PHOSPHATE BINDING AGENT; PROCAINAMIDE; SULFADIAZINE SILVER;

APNEA; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM DEPRESSION; CHRONIC KIDNEY DISEASE; CONFERENCE PAPER; CRYSTALLURIA; DROWSINESS; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG METABOLISM; GASTROINTESTINAL PAIN; HUMAN; HYPOTENSION; LEUKOPENIA; PRIORITY JOURNAL; QT PROLONGATION; RESPIRATION DEPRESSION; SEDATION; SEIZURE; SIDE EFFECT; SINUS ARREST; SINUS BRADYCARDIA;

DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOXICITY; HUMANS; KIDNEY FAILURE, CHRONIC; MALABSORPTION SYNDROMES; PHARMACOKINETICS;

EID: 33845798410     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000096412     Document Type: Conference Paper

References (29)

1. Manley HJ, Garvin CG, Drayer DK, Reid GM, Bender WL, Neufeld TK, Hebbar S, Muther RS: Medication prescribing patterns in ambulatory haemodialysis patients: comparisons of USRDS to a large not-for-profit dialysis provider. Nephrol Dial Transplant 2004;19:1842-1848.
2. Kaplan B, Mason NA, Shimp LA, Ascione FJ: Chronic hemodialysis patients. Part I: Characterization and drug-related problems. Ann Pharmacother 1994:28:316-319.
3. Aspden P, Wolcott J, Bootman JL, Cronenwett LR (eds), Committee on Identifying and Preventing Medication Errors: Preventing Medication Errors: Quality Chasm Series. Institute of Medicine of the National Academies. Washington, National Academy Press, 2006.
4. Manley HJ, Cannella CA, Bailie GR, St Peter WL: Medication-related problems in ambulatory hemodialysis patients: a pooled analysis. Am J Kidney Dis 2005;46:669-680.
5. Gabardi S, Abramson S: Drug dosing in chronic kidney disease. Med Clin North Am 2005;89:649-687.
6. Ala-Kaila K: Gastric secretion kinetics in chronic renal failure. Scand J Gastroenterol 1987;22:1185-1192.
7. Tilstone WJ, Fine A: Furosemide kinetics in renal failure. Clin Pharmacol Ther 1978:23:644-650.
8. O'Neil-Cutting MA, Crosby WH: The effect of antacids on the absorption of simultaneously ingested iron. JAMA 1986;255:1468-1470.
9. Kays MB, Overholser BR, Mueller BA, Moe SM, Sowinski KM: Effects of sevelamer hydrochloride and calcium acetate on the oral bioavailability of ciprofloxacin. Am J Kidney Dis 2003;42:1253-1259.
10. Clinical practice guidelines for nutrition in chronic renal failure. K/DOQI, National Kidney Foundation. Am J Kidney Dis 2000;35(suppl 2):S1-S140.
11. Mueller BA, Brierton DG, Abel SR, Bowman L: Effect of enteral feeding with Ensure® on the oral bioavailability of ofloxacin and ciprofloxacin. Antimicrob Agents Chemother 1994;38:2101-2105.
12. Kanji S, McKinnon PS, Barletta JF; Kruse JA, Devlin JW: Bioavailability of gatifloxacin by gastric tube administration with and without concomitant enteral feeding in critically ill patients. Crit Care Med 2003;31:1347-1352.
13. Gelber RP, Kurth T, Kausz AT, Manson JE, Buring JE, Levey AS, Gaziano JM: Association between body mass index and CKD in apparently healthy men. Am J Kidney Dis 2005;46:871-880.
14. Duffull SB, Dooley MJ, Green B, Poole SG, Kirkpatrick CM: A standard weight descriptor for dose adjustment in the obese patient. Clin Pharmacokinet 2004:43:1167-1178.
15. Bearden DT, Rodvold KA: Dosage adjustment for antibacterials in obese patients. Clin Pharmacokinet 2000;38:415-426.
16. Erstad BL: Dosing of medications in morbidly obese patients in the intensive care unit setting. Intensive Care Med 2004;30:18-32.
17. Boobis SW: Alteration of plasma albumin in relation to decreased drug binding in uremia. Clin Pharmacol Ther 1977;22:147-153.
18. Sjoholm I, Kober A, Odar-Cederlof I, Borgaa O: Protein binding of drugs in uremic and normal serum: the role of endogenous binding inhibitors. Biochem Pharmacol 1976;25:1205-1213.
19. Reuning RH, Sams RA, Notari RE: Role of pharmacokinetics in drug dosing adjustment. I. Pharmacologic effect kinetics and apparent volume of distribution of digoxin. J Clin Pharmacol New Drugs 1973;13:127-141.
20. Lam YW, Banerji S, Hatfield C, Talbert RL: Principles of drug administration in renal insufficiency. Clin Pharmacokinet 1997;32:30-57.
21. Graves SW, Brown B, Valdes R: An endogenous digoxin-like substance in patients with renal impairment. Ann Intern Med 1983;99:604-608.
22. Gibson TP: Renal disease and drug metabolism: an overview. Am J Kidney Dis 1986;1:7-17.
23. Elston AC, Bayliss MK, Park GR: Effect of renal failure on drug metabolism by the liver. Br J Anaesth 1993;71:282-290.
24. Nolin TD, Appiah K, Kendrick SA, Le P, McMonagle E, Himmelfarb J: Hemodialysis acutely improves hepatic CYP3A4 metabolic activity. J Am Soc Nephrol 2006;17:2363-2367.
25. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999;130:461-470.
26. Stevens LA, Coresh J, Greene T, Levey AS: Assessing kidney function - measured and estimated glomerular filtration rate. N Engl J Med 2006;354:2473-2483.
27. Vidal L, Shavit M, Fraser A, Paul M, Leibovici L: Systematic comparison of four sources of drug information regarding adjustment of dose for renal function. BMJ 2005;331:26366.
28. Thompson Micromedex Healthcare Series, 2006, vol 129.
29. Bennett WM, Aronoff GR, Golper TA, et al: Drug Prescribing in Renal Failure. Philadelphia, American College of Physicians, 1994.